Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51

Cancer Treatment Reviews

Volumn 41, Issue 1, 2015, Pages 35-45

  Ward, Ambber ^a   Khanna, Kum Kum ^a   Wiegmans, Adrian P ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Combination therapy; DNA damage response; Homologous recombination; RAD51; Synthetic lethality; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; BRCA1 PROTEIN; HISTONE DEACETYLASE INHIBITOR; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEOTIDYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAD51 INHIBITOR; RAD51 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CELL MOTILITY; CHRONIC MYELOID LEUKEMIA; DNA BINDING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFICACY; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIPLE CANCER; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; ANTAGONISTS AND INHIBITORS; GENETICS; NEOPLASMS; PROCEDURES;

DNA DAMAGE; DNA REPAIR; HOMOLOGOUS RECOMBINATION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RAD51 RECOMBINASE;

EID: 84918799959     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.10.006     Document Type: Review

References (84)

1. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411(6835):366-374.
2. Jackson S.P. The DNA-damage response: new molecular insights and new approaches to cancer therapy. Biochem Soc Trans 2009, 37(Pt 3):483-494.
3. Woods D., Turchi J.J. Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther 2013, 14(5):379.
4. Duker N.J. Chromosome breakage syndromes and cancer. Am J Med Genet 2002, 115(3):125-129.
5. Jalal S., Earley J.N., Turchi J.J. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res 2011, 17(22):6973-6984.
6. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921.
7. Strom C.E., Johansson F., Uhlen M., Szigyarto C.A., Erixon K., Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res 2011, 39(8):3166-3175.
8. Mansour W.Y., Rhein T., Dahm-Daphi J. The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic Acids Res 2010, 38(18):6065-6077.
9. Juvekar A., Burga L.N., Hu H., Lunsford E.P., Ibrahim Y.H., Balmana J., et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012, 2(11):1048-1063.
10. Norquist B., Wurz K.A., Pennil C.C., Garcia R., Gross J., Sakai W., et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011, 29(22):3008-3015.
11. Schild D., Wiese C. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res 2010, 38(4):1061-1070.
12. Ibrahim Y.H., Garcia-Garcia C., Serra V., He L., Torres-Lockhart K., Prat A., et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012, 2(11):1036-1047.
13. Lord C.J., Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013, 19(11):1381-1388.
14. Hine C.M., Seluanov A., Gorbunova V. Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci USA 2008, 105(52):20810-20815.
15. Hine C.M., Li H., Xie L., Mao Z., Seluanov A., Gorbunova V. Regulation of Rad51 promoter. Cell Cycle 2014, 13(13).
16. Nagathihalli N.S., Nagaraju G. RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. BBA-Rev Cancer 2011, 1816(2):209-218.
17. Maacke H., Opitz S., Jost K., Hamdorf W., Henning W., Krüger S., et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 2000, 88(6):907-913.
18. Maacke H., Jost K., Opitz S., Miska S., Yuan Y., Hasselbach L., et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000, 19(23):2791-2795.
19. Hannay J.A.F., Liu J., Zhu Q.-S., Bolshakov S.V., Li L., Pisters P.W.T., et al. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 2007, 6(5):1650-1660.
20. Takenaka T., Yoshino I., Kouso H., Ohba T., Yohena T., Osoegawa A., et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 2007, 121(4):895-900.
21. Mitra A., Jameson C., Barbachano Y., Sanchez L., Kote-Jarai Z., Peock S., et al. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 2009, 55(6):696-704.
22. Raderschall E., Stout K., Freier S., Suckow V., Schweiger S., Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002, 62(1):219-225.
23. Wiegmans A.P., Al-Ejeh F., Chee N., Yap P.-Y., Gorski J.J., Silva L.D., et al. Rad51 supports triple negative breast cancer metastasis. Oncotarget 2014.
24. Short S.C., Giampieri S., Worku M., Alcaide-German M., Sioftanos G., Bourne S., et al. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Neuro-oncol 2011, 13(5):487-499.
25. Kiyohara E., Tamai K., Katayama I., Kaneda Y. The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma. Gene Ther 2012, 19(7):734-741.
26. Barbano R., Copetti M., Perrone G., Pazienza V., Muscarella L.A., Balsamo T., et al. High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. Int J Cancer 2011, 129(3):536-545.
27. Graeser M., McCarthy A., Lord C.J., Savage K., Hills M., Salter J., et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010, 16(24):6159-6168.
28. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15):4429-4434.
29. Pellegrini L., David S.Y., Lo T., Anand S., Lee M., Blundell T.L., et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002, 420(6913):287-293.
30. Aihara H., Ito Y., Kurumizaka H., Yokoyama S., Shibata T. The N-terminal domain of the human Rad51 protein binds DNA: structure and a DNA binding surface as revealed by NMR. J Mol Biol 1999, 290(2):495-504.
31. Ogawa T., Yu X., Shinohara A., Egelman E.H. Similarity of the yeast RAD51 filament to the bacterial RecA filament. Science 1993, 259(5103):1896-1899.
32. Suwaki N., Klare K., Tarsounas M. RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin Cell Dev Biol 2011, 22(8):898-905.
33. Sonoda E., Sasaki M.S., Buerstedde J.-M., Bezzubova O., Shinohara A., Ogawa H., et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 1998, 17(2):598-608.
34. Ito M., Yamamoto S., Nimura K., Hiraoka K., Tamai K., Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005, 7(8):1044-1052.
35. Shenouda S.K., Alahari S.K. MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer Metastasis Rev 2009, 28(3-4):369-378.
36. Mueller A.C., Sun D., Dutta A. The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene 2013, 32(9):1164-1172.
37. Gasparini P., Lovat F., Fassan M., Casadei L., Cascione L., Jacob N.K., et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. PNAS 2014.
38. Wang Y., Huang J.-W., Calses P., Kemp C.J., Taniguchi T. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res 2012, 72(16):4037-4046.
39. Neijenhuis S., Bajrami I., Miller R., Lord C.J., Ashworth A. Identification of miRNA modulators to PARP inhibitor response. DNA Repair 2013, 12(6):394-402.
40. Jackson A.L., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003, 21(6):635-637.
41. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23(4):457-462.
42. Jackson A.L., Linsley P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010, 9(1):57-67.
43. Grimm D., Kay M.A. RNAi and gene therapy: a mutual attraction. Hematology 2007, 1:473-481.
44. Choudhury A., Zhao H., Jalali F., AL Rashid S., Ran J., Supiot S., et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 2009, 8(1):203-213.
45. Tibes R., Fine G., Choy G., Redkar S., Taverna P., Oganesian A., et al. A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013, 71(2):463-471.
46. Welsh J.W., Mahadevan D., Ellsworth R., Cooke L., Bearss D., Stea B. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol. 2009, 4:69.
47. Zhao H., Luoto K.R., Meng A.X., Bristow R.G. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio-and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol 2011, 101(1):59-65.
48. Tsai M.-S., Kuo Y.-H., Chiu Y.-F., Su Y.-C., Lin Y.-W. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J Pharmacol Exp Ther 2010, 335(3):830-840.
49. Kachhap S.K., Rosmus N., Collis S.J., Kortenhorst M.S.Q., Wissing M.D., Hedayati M., et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS ONE 2010, 5(6):e11208.
50. Xie C., Drenberg C., Edwards H., Caldwell J.T., Chen W., Inaba H., et al. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS ONE 2013, 8(11):e79106.
51. Chen X., Wong P., Radany E.H., Stark J.M., Laulier C., Wong J.Y.C. Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res 2012, 10(8):1052-1064.
52. Sampath D., Zecevic A., Ewald B., Hayes M., Liu C., Marcucci G., et al. Panobinostat, an oral pan-histone deacetylase (HDAC) inhibitor activates a micro RNA signature that targets Rad51 to attenuate homologous DNA repair and sensitize AML Cells to sapacitabine. Blood 2013, 122(21):822.
53. Adimoolam S., Sirisawad M., Chen J., Thiemann P., Ford J.M., Buggy J.J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. PNAS 2007, 104(49):19482-19487.
54. Du L.-Q., Du X.-Q., Bai J.-Q., Wang Y., Yang Q.-S., Wang X.-C., et al. Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells. J Cancer Res Clin Oncol 2012, 1-8.
55. Martinez S.F., Renodon-Cornière A., Nomme J., Eveillard D., Fleury F., Takahashi M., et al. Targeting human Rad51 by specific DNA aptamers induces inhibition of homologous recombination. Biochimie 2010, 92(12):1832-1838.
56. Ganten D., Ruckpaul K., Birchmeier W., Epplen J.T., Genser K., Gossen M., et al. Encyclopedic reference of genomics and proteomics in molecular medicine 2006, Springer.
57. Arkin M.R., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004, 3(4):301-317.
58. Takaku M., Kainuma T., Ishida-Takaku T., Ishigami S., Suzuki H., Tashiro S., et al. Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51. Genes Cells 2011, 16(4):427-436.
59. Huang F., Motlekar N.A., Burgwin C.M., Napper A.D., Diamond S.L., Mazin A.V. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol 2011, 6(6):628-635.
60. Huang F., Mazina O.M., Zentner I.J., Cocklin S., Mazin A.V. Inhibition of homologous recombination in human cells by targeting RAD51 recombinase. J Med Chem 2012, 55(7):3011-3020.
61. Huang F., Mazin A.V. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS ONE 2014, 9(6):e100993.
62. Budke B., Kalin J.H., Pawlowski M., Zelivianskaia A.S., Wu M., Kozikowski A.P., et al. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem 2012, 254-263.
63. Budke B., Logan H.L., Kalin J.H., Zelivianskaia A.S., McGuire W.C., Miller L.L., et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res 2012, 40(15):7347-7357.
64. Zhu J., Zhou L., Wu G., Konig H., Lin X., Li G., et al. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med 2013, 5(3):353-365.
65. Slupianek A., Jozwiakowski S.K., Gurdek E., Skorski T. BCR/ABL kinase interacts with and phosphorylates the RAD51 paralog, RAD51B. Leukemia 2009, 23(12):2308-2310.
66. McCabe N., Turner N.C., Lord C.J., Kluzek K., Białkowska A., Swift S., et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-Ribose) polymerase inhibition. Cancer Res 2006, 66(16):8109-8115.
67. Tennstedt P., Fresow R., Simon R., Marx A., Terracciano L., Petersen C., et al. RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. Int J Cancer 2013, 132(9):2118-2126.
68. Conway A.B., Lynch T.W., Zhang Y., Fortin G.S., Fung C.W., Symington L.S., et al. Crystal structure of a Rad51 filament. Nat Struct Mol Biol 2004, 11(8):791-796.
69. Fokas E., Prevo R., Hammond E.M., Brunner T.B., McKenna W.G., Muschel R.J. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev 2014, 40(1):109-117.
70. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134.
71. Barber L.J., Sandhu S., Chen L.N., Campbell J., Kozarewa I., Fenwick K., et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013, 229(3):422-429.
72. Konstantinopoulos P.A., Wilson A.J., Saskowski J., Wass E., Khabele D. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol 2014, 133(3):599-606.
73. Munster P.N., Marchion D., Thomas S., Egorin M., Minton S., Springett G., et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009, 101(7):1044-1050.
74. Daemen A., Wolf D., Korkola J., Griffith O., Frankum J., Brough R., et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 2012, 135(2):505-517.
75. Tahara M., Inoue T., Sato F., Miyakura Y., Horie H., Yasuda Y., et al. The use of olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks. Mol Cancer Ther 2014.
76. Yang Z., Waldman A.S., Wyatt M.D. Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol 2012, 83(6):741-746.
77. Quiros S., Roos W.P., Kaina B. Rad51 and BRCA2 - new molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS ONE 2011, 6(11):e27183.
78. Martin R.W., Orelli B.J., Yamazoe M., Minn A.J., Takeda S., Bishop D.K. RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 2007, 67(20):9658-9665.
79. Dhillon K.K., Swisher E.M., Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 2011, 102(4):663-669.
80. Jaspers J.E., Kersbergen A., Boon U., Sol W., van Deemter L., Zander S.A., et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 2013, 3(1):68-81.
81. Huntoon C.J., Flatten K.S., Hendrickson A.E.W., Huehls A.M., Sutor S.L., Kaufmann S.H., et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res 2013, 73(12):3683-3691.
82. Lim D.-S., Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 1996, 16(12):7133-7143.
83. Takai H., Tominaga K., Motoyama N., Minamishima Y.A., Nagahama H., Tsukiyama T., et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1-/- mice. Genes Dev 2000, 14(12):1439-1447.
84. Barrington R.A., Fasullo M., Knight K.L. A role for RAD51 in the generation of immunoglobulin gene diversity in rabbits. J Immunol 1999, 162(2):911-919.